Skip to main content
Top
Published in: Strahlentherapie und Onkologie 1/2016

01-01-2016 | Original Article

Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma

Authors: Margret Rave-Fränk, Narges Tehrany, Dr. med. Julia Kitz, Martin Leu, Dr. med. Hanne Elisabeth Weber, Prof. Dr. med. Peter Burfeind, Prof. Dr. med. Henning Schliephake, Prof. Dr. med. Martin Canis, Prof. Dr Tim Beissbarth, Prof. Dr Holger Michael Reichardt, PD Dr. med. Hendrik Andreas Wolff

Published in: Strahlentherapie und Onkologie | Issue 1/2016

Login to get access

Abstract

Objective

The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy.

Methods

Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16INK4A status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression.

Results

CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16INK4A positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034).

Conclusion

A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.
Literature
1.
go back to reference Heiduschka G, Grah A, Oberndorfer F et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191:209–216PubMedCrossRef Heiduschka G, Grah A, Oberndorfer F et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191:209–216PubMedCrossRef
2.
go back to reference Takes RP, Rinaldo A, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol 48:775–779PubMedCrossRef Takes RP, Rinaldo A, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol 48:775–779PubMedCrossRef
3.
go back to reference Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230PubMedCrossRef Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230PubMedCrossRef
4.
go back to reference Albert S, Riveiro ME, Halimi C et al (2013) Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. Head Neck 35:1819–1828PubMedCrossRef Albert S, Riveiro ME, Halimi C et al (2013) Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. Head Neck 35:1819–1828PubMedCrossRef
5.
go back to reference Katayama A, Ogino T, Bandoh N et al (2005) Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 11:2937–2946PubMedCrossRef Katayama A, Ogino T, Bandoh N et al (2005) Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 11:2937–2946PubMedCrossRef
6.
go back to reference Uchida D, Onoue T, Tomizuka Y et al (2007) Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 5:685–694PubMedCrossRef Uchida D, Onoue T, Tomizuka Y et al (2007) Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 5:685–694PubMedCrossRef
7.
go back to reference Salcedo R, Wasserman K, Young HA et al (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125–1135PubMedPubMedCentralCrossRef Salcedo R, Wasserman K, Young HA et al (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125–1135PubMedPubMedCentralCrossRef
8.
go back to reference Ishikawa T, Nakashiro K, Hara S et al (2006) CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 28:61–66PubMed Ishikawa T, Nakashiro K, Hara S et al (2006) CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 28:61–66PubMed
10.
go back to reference Ueda M, Shimada T, Goto Y et al (2010) Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx 37:488–495PubMedCrossRef Ueda M, Shimada T, Goto Y et al (2010) Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx 37:488–495PubMedCrossRef
11.
go back to reference Clatot F, Picquenot JM, Choussy O et al (2011) Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 47:1062–1068PubMedCrossRef Clatot F, Picquenot JM, Choussy O et al (2011) Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 47:1062–1068PubMedCrossRef
12.
go back to reference Tehrany N, Kitz J, Rave-Fränk M et al (2015) High-grade acute organ toxicity and p16 expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma. Strahlenther Onkol 191:566–572PubMedCrossRef Tehrany N, Kitz J, Rave-Fränk M et al (2015) High-grade acute organ toxicity and p16 expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma. Strahlenther Onkol 191:566–572PubMedCrossRef
13.
go back to reference Wolff HA, Bosch J, Jung K et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef Wolff HA, Bosch J, Jung K et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef
14.
go back to reference Wolff HA, Daldrup B, Jung K et al (2011) High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. Radiology 258:864–871PubMedCrossRef Wolff HA, Daldrup B, Jung K et al (2011) High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. Radiology 258:864–871PubMedCrossRef
15.
go back to reference Meng X, Wuyi L, Yuhong X et al (2010) Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation. J Oral Pathol Med 39:63–68PubMedCrossRef Meng X, Wuyi L, Yuhong X et al (2010) Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation. J Oral Pathol Med 39:63–68PubMedCrossRef
16.
go back to reference Li KC, Huang YH, Ho CY et al (2012) The role of IL-8 in the SDF-1alpha/CXCR4-induced angiogenesis of laryngeal and hypopharyngeal squamous cell carcinoma. Oral Oncol 48:507–515PubMedCrossRef Li KC, Huang YH, Ho CY et al (2012) The role of IL-8 in the SDF-1alpha/CXCR4-induced angiogenesis of laryngeal and hypopharyngeal squamous cell carcinoma. Oral Oncol 48:507–515PubMedCrossRef
17.
go back to reference Uchida D, Onoue T, Kuribayashi N et al (2011) Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 47:452–459PubMedCrossRef Uchida D, Onoue T, Kuribayashi N et al (2011) Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 47:452–459PubMedCrossRef
18.
go back to reference Ou DL, Chien HF, Chen CL et al (2008) Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 28:1355–1359PubMed Ou DL, Chien HF, Chen CL et al (2008) Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 28:1355–1359PubMed
19.
go back to reference Taki M, Higashikawa K, Yoneda S et al (2008) Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 19:993–998PubMed Taki M, Higashikawa K, Yoneda S et al (2008) Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 19:993–998PubMed
20.
go back to reference Ishikawa T, Nakashiro K, Klosek SK et al (2009) Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep 21:707–712PubMed Ishikawa T, Nakashiro K, Klosek SK et al (2009) Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep 21:707–712PubMed
21.
go back to reference Ramsey DM, McAlpine SR (2013) Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett 23:20–25PubMedCrossRef Ramsey DM, McAlpine SR (2013) Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett 23:20–25PubMedCrossRef
22.
go back to reference McDermott DH, Liu Q, Velez D et al (2014) A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 123:2308–2316PubMedPubMedCentralCrossRef McDermott DH, Liu Q, Velez D et al (2014) A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 123:2308–2316PubMedPubMedCentralCrossRef
23.
go back to reference Cipriani NA, Blair E, Taxy JB (2010) WHIM syndrome and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:105–108PubMedCrossRef Cipriani NA, Blair E, Taxy JB (2010) WHIM syndrome and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:105–108PubMedCrossRef
24.
go back to reference Clatot F, Gouerant S, Mareschal S et al (2014) The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol 50:200–207PubMedCrossRef Clatot F, Gouerant S, Mareschal S et al (2014) The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol 50:200–207PubMedCrossRef
25.
go back to reference Rainsbury JW, Ahmed W, Williams HK et al (2013) Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 35:1048–1055PubMedCrossRef Rainsbury JW, Ahmed W, Williams HK et al (2013) Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 35:1048–1055PubMedCrossRef
Metadata
Title
Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma
Authors
Margret Rave-Fränk
Narges Tehrany
Dr. med. Julia Kitz
Martin Leu
Dr. med. Hanne Elisabeth Weber
Prof. Dr. med. Peter Burfeind
Prof. Dr. med. Henning Schliephake
Prof. Dr. med. Martin Canis
Prof. Dr Tim Beissbarth
Prof. Dr Holger Michael Reichardt
PD Dr. med. Hendrik Andreas Wolff
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 1/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0892-5

Other articles of this Issue 1/2016

Strahlentherapie und Onkologie 1/2016 Go to the issue